Panavance Therapeutics
  • Our Science
    • Pipeline
    • About Misetionamide
    • MOA
  • About
    • About Panavance
    • Leadership
    • Advisors & Collaborators
    • Contact Panavance
  • Resources
    • Publications
    • Brochures
    • Videos
    • Press Releases
    • Events
  • Participate

Let’s engage.

GP- 2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP- Kinase and impairs the NF- kB pathway in pancreatic cancer cells

December 31, 2023 / 0 Minute Read

panavance therapeutics

  • Our Science
  • About
  • Resources
  • Participate
  • LinkedIn
  • Twitter
  • Facebook

+1.610.922.1910

Copyright © 2025 Panavance Therapeutics Inc.